A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Inclusion Criteria: * Individuals who participated in a previous study of gevokizumab in PG * A clinical diagnosis of classic pyoderma gangrenosum * Contraceptive measures adequate to prevent pregnancy during the study Exclusion Criteria: * Clinical evidence of acutely infected pyoderma gangrenosum * History of allergic or anaphylactic reactions to monoclonal antibodies * History of recurrent or chronic systemic infections * Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding Other protocol-defined inclusion/exclusion criteria may apply